Role of intercellular communications in breast cancer multicellular tumor spheroids after chemotherapy

被引:8
作者
Oktem, G. [1 ]
Bilir, A.
Ayla, S.
Yavasoglu, A.
Goksel, G.
Saydam, G.
Uysal, A.
机构
[1] Ege Univ, Sch Med, Dept Histol & Embryol, TR-35100 Izmir, Turkey
[2] Istanbul Univ, Sch Med, Dept Histol & Embryol, TR-34390 Istanbul, Turkey
[3] Celal Bayar Univ, Sch Med, Dept Oncol, TR-54030 Manisa, Turkey
[4] Ege Univ, Sch Med, Dept Hematol, TR-35100 Izmir, Turkey
关键词
occludin; connexin-43; breast cancer spheroid; doxorubicin; docetaxel;
D O I
10.3727/000000006783981071
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tumor heterogeneity is an important feature that is especially involved in tumor aggressiveness. Multicellular tumor spheroids (MTS) may provide some benefits in different steps for investigation of the aggregation, organization, differentiation, and network formation of tumor cells in 3D space. This model offers a unique opportunity for improvements in the capability of a current strategy to detect the effect of an appropriate anticancer agent. The aim of this study was to investigate the cellular interactions and morphological changes following chemotherapy in a 3D breast cancer spheroid model. Distribution of the gap junction protein "connexin-43" and the tight junction protein "occludin" was investigated by immunohistochemistry. Cellular interactions were examined by using transmission and scanning electron microscopies as well as light microscopy with Giemsa staining after treating cells with doxorubicin, docetaxel, and doxorubicin/docetaxel combination. Statistical analyses showed significant changes and various alterations that were observed in all groups; however, the most prominent effect was detected in the doxorubicin/docetaxel combination group. Distinct composition as a vessel-like structure and a pseudoglandular pattern of control spheroids were detected in drug-administered groups. Immunohistochemical results were consistent with the ultrastructural changes. In conclusion, doxorubicin/docetaxel combination may be more effective than the single drug usage as shown in a 3D model. The MTS model has been found to be an appropriate and reliable method for the detection of the changes in the expression of cellular junction proteins as well as other cellular proteins occurring after chemotherapy. The MTS model can be used to validate the effects of various combinations or new chemotherapeutic agents as well as documentation of possible mechanisms of new drugs.
引用
收藏
页码:225 / 233
页数:9
相关论文
共 31 条
[1]   Interspecies diversity of the occludin sequence: cDNA cloning of human, mouse, dog, and rat-kangaroo homologues [J].
AndoAkatsuka, Y ;
Saitou, M ;
Hirase, T ;
Kishi, M ;
Sakakibara, A ;
Itoh, M ;
Yonemura, S ;
Furuse, M ;
Tsukita, S .
JOURNAL OF CELL BIOLOGY, 1996, 133 (01) :43-47
[2]   Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study [J].
Ardavanis, A ;
Tryfonopoulos, D ;
Alexopoulos, A ;
Kandylis, C ;
Lainakis, G ;
Rigatos, G .
BRITISH JOURNAL OF CANCER, 2005, 92 (04) :645-650
[3]  
Balda MS, 1998, J CELL SCI, V111, P541
[4]  
BENNETT MVL, 1991, NEURON, V6, P305, DOI 10.1016/0896-6273(91)90241-Q
[5]  
BEYER EC, 1990, J BIOL CHEM, V265, P14439
[6]   Localization of apical epithelial determinants by the basolateral PDZ protein Scribble [J].
Bilder, D ;
Perrimon, N .
NATURE, 2000, 403 (6770) :676-680
[7]   FORMATION AND GROWTH OF MULTICELLULAR SPHEROIDS OF HUMAN-ORIGIN [J].
CARLSSON, J ;
NILSSON, K ;
WESTERMARK, B ;
PONTEN, J ;
SUNDSTROM, C ;
LARSSON, E ;
BERGH, J ;
PAHLMAN, S ;
BUSCH, C ;
COLLINS, VP .
INTERNATIONAL JOURNAL OF CANCER, 1983, 31 (05) :523-533
[8]   Upregulation of gap junctional intercellular communication and connexin 43 expression by cyclic-AMP and all-trans-retinoic acid is associated with glutathione depletion and chemosensitivity in neuroblastoma cells [J].
Carystinos, GD ;
Alaoui-Jamali, MA ;
Phipps, J ;
Yen, L ;
Batist, G .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2001, 47 (02) :126-132
[9]  
Freyer JP, 1998, J CELL PHYSIOL, V176, P138, DOI 10.1002/(SICI)1097-4652(199807)176:1<138::AID-JCP16>3.3.CO
[10]  
2-7